Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review

被引:31
作者
Zheng, Haixiang [1 ,4 ]
Sechi, Leonardo Antonio [1 ,5 ]
Navarese, Eliano Pio [3 ]
Casu, Gavino [3 ]
Vidili, Gianpaolo [2 ]
机构
[1] Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy
[2] Univ Sassari, Dept Med Surg & Pharm, I-07100 Sassari, Italy
[3] Univ Sassari, Clin & Expt Cardiol, Clin & Intervent Cardiol, Sassari, Italy
[4] Shantou Univ, Dept Cardiol, Affiliated Hosp 2, Med Coll, Shantou 515041, Peoples R China
[5] AOU Sassari, Complex Struct Microbiol & Virol, I-07100 Sassari, Italy
关键词
Metabolic dysfunction-associated steatotic liver disease; Nonalcoholic fatty liver disease; Metabolic-associated fatty liver disease; Cardiovascular risk; MAGNETIC-RESONANCE ELASTOGRAPHY; NONALCOHOLIC STEATOHEPATITIS; TRANSIENT ELASTOGRAPHY; INSULIN-RESISTANCE; FIBROSIS; VARIANT; HEART; MAFLD; NAFLD; GENE;
D O I
10.1186/s12933-024-02434-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.
引用
收藏
页数:20
相关论文
共 152 条
[51]   Metabolic-associated fatty liver disease and lipoprotein metabolism [J].
Heeren, Joerg ;
Scheja, Ludger .
MOLECULAR METABOLISM, 2021, 50
[52]   Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics [J].
Huang, Gary ;
Wallace, Daniel F. ;
Powell, Elizabeth E. ;
Rahman, Tony ;
Clark, Paul J. ;
Subramaniam, V. Nathan .
BIOMEDICINES, 2023, 11 (10)
[53]  
Iqra Nadeem Kazi M, 2024, Gastroenterol Hepatol, V20
[54]   Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease [J].
Janssen, Arne ;
Grobbee, Diederick E. ;
Dendale, Paul .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2020, 27 (10) :1059-1063
[55]   Genetic and epigenetic factors determining NAFLD risk [J].
Jonas, Wenke ;
Schuermann, Annette .
MOLECULAR METABOLISM, 2020, 50
[56]  
Kang MK, 2024, Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification
[57]   NAFLD and cardiovascular diseases: a clinical review [J].
Kasper, Philipp ;
Martin, Anna ;
Lang, Sonja ;
Kuetting, Fabian ;
Goeser, Tobias ;
Demir, Muenevver ;
Steffen, Hans-Michael .
CLINICAL RESEARCH IN CARDIOLOGY, 2021, 110 (07) :921-937
[58]   Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver [J].
Kaya, Eda ;
Yilmaz, Yusuf .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (02) :329-338
[59]   Pericardial Fat and the Risk of Heart Failure [J].
Kenchaiah, Satish ;
Ding, Jingzhong ;
Carr, J. Jeffrey ;
Allison, Matthew A. ;
Budoff, Matthew J. ;
Tracy, Russell P. ;
Burke, Gregory L. ;
McClelland, Robyn L. ;
Arai, Andrew E. ;
Bluemke, David A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (21) :2638-2652
[60]   Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With ST-Segment Elevation Myocardial Infarction [J].
Keskin, Muhammed ;
Hayiroglu, Mert Ilker ;
Uzun, Ahmet Okan ;
Guvenc, Tolga Sinan ;
Sahin, Sinan ;
Kozan, Omer .
AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (10) :1720-1726